New antiepileptic drugs currently in clinical trials: Is there a strategy in their development?

Therapeutic Drug Monitoring

Volumn 24, Issue 1, 2002, Pages 85-90

  Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

New antiepileptic drugs; Pharmacodynamic based drug design; Pharmacokinetic based drug design; Second generation antiepileptic drugs

Indexed keywords

1 (4 CHLOROPHENYL) 4 MORPHOLINO 3 IMIDAZOLIN 2 ONE; 2 HYDROXYPROPYLVALPROMIDE; 2 ISOPROPYLVALERAMIDE; ABS 103; ANTICONVULSIVE AGENT; CONANTOKIN G; ETIRACETAM; FELBAMATE; FLUOROFELBAMATE; GABAPENTIN; HARKOSERIDE; ISOVALERAMIDE; LAMOTRIGINE; N METHYL 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; NEW DRUG; OXCARBAZEPINE; PREGABALIN; RETIGABINE; RUFINAMIDE; SAFINAMIDE; SPD 421; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID DERIVATIVE; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE;

ANTICONVULSANTS; CLINICAL TRIALS; DRUG DESIGN; EPILEPSY; HUMANS; VALPROIC ACID;

EID: 0036146487     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200202000-00015     Document Type: Conference Paper

References (21)

1. Antiepileptic drugs
2. New antiepileptic drugs
3. Progress report on new antiepileptic drugs: A summary of the fifth Eilat Conference (EILAT V)
4. Progress report on new antiepileptic drugs: A summary of the fourth Eilat Conference (EILAT IV)
5. Progress report on new antiepileptic drugs: A summary of the third Eilat conference
6. Enantioselective pharmacokinetics of 10 hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects
7. Pharmacokinetic consideration in the design of better and safer new antiepileptic drugs
8. Valproic acid teratogenesis
9. Valproic acid induced neural tube defects in mice and humans: Aspects of chirality, alternative drug development, pharmacokinetics, and possible mechanism
10. Can we develop improved derivatives of valproic acid?
11. Single-dose tolerance and pharmacokinetics of 2-n propyl-2(E)-pentanoate (Δ2(e)-valproate) in healthy male volunteers
12. A new analogue of valproic acid with improved anticonvulsant properties and low teratogenic and neurotoxic potential in experimental animals
13. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide-a CNS-active chiral amide of valproic acid
14. Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxy valpromide, a CNS-active valproyamide
15. Disposition of two tetramethyl cyclopropane analogues of valpromide in the brain, liver, plasma, and urine of rats
16. Anticonvulsant profile of valrocemide (TV 1901): A new antiepileptic drug
17. Chiral switches
18. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin
19. Fluorofelbamate: Pharmacokinetic and metabolic profile of a potent anti-convulsant
20. Preparation and anticonvulsant activity of a series of functionalized heteroatom-substituted amino acids